donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

ARCT Arcturus Therapeutics

19.180
+2.150+12.62%
Close 08/12 16:00 ET
19.18000.00%
Post Mkt Price 08/12 16:30 ET
High
20.180
Open
17.360
Turnover
14.68M
Low
17.360
Pre Close
17.030
Volume
768.42K
Market Cap
509.73M
P/E(TTM)
Loss
52wk High
58.450
Shares
26.58M
P/E(Static)
Loss
52wk Low
11.700
Float Cap
434.08M
Bid/Ask %
-66.67%
Historical High
129.710
Shs Float
22.63M
Volume Ratio
1.31
Historical Low
4.110
Dividend TTM
--
Div Yield TTM
--
P/B
2.99
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
3.40%
Amplitude
16.56%
Avg Price
19.100
Lot Size
1
Float Cap
434.08M
Bid/Ask %
-66.67%
Historical High
129.710
Shs Float
22.63M
Volume Ratio
1.31
Historical Low
4.110
Dividend TTM
--
P/B
2.99
Dividend LFY
--
Turnover Ratio
3.40%
Amplitude
16.56%
Avg Price
19.100
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company’s development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
CEO: Payne M.Sc., Joseph E.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...